An announcement from Oruka Therapeutics ( (ORKA) ) is now available.
Oruka Therapeutics has completed its merger with ARCA biopharma and a $275 million private placement. The company, focusing on chronic skin diseases treatment, will trade on Nasdaq under “ORKA.” Samarth Kulkarni, CEO of CRISPR Therapeutics, is appointed as Board Chairman. Oruka aims to advance its lead programs into clinical trials and release initial data for ORKA-001 next year.
For detailed information about ORKA stock, go to TipRanks’ Stock Analysis page.
